Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00325728|
Recruitment Status : Completed
First Posted : May 15, 2006
Last Update Posted : August 14, 2017
|Condition or disease||Intervention/treatment||Phase|
|Chronic Insomnia||Drug: Ramelteon Drug: Placebo||Phase 2|
Epidemiological data for 2005 show that an estimated 4.2 million people in the US suffer from Alzheimer's disease, often necessitating caregiver assistance, which can in many cases progress to institutionalization. Subjects with Alzheimer's disease dementia frequently experience disturbed sleep patterns characterized by insufficient nocturnal sleep and excessive daytime napping, which has been associated with both cognitive and behavioral pathology such as impaired daytime functioning, agitation, and nocturnal wandering.
Although the causality of sleep disturbances in Alzheimer's disease remains unclear; some research suggests that the fragmented sleep and associated behavioral disturbances could be related to the degeneration of the serotonergic and noradrenergic innervation of suprachiasmatic nucleus andsubsequent disruption in melatonin secretion patterns. Additionally, research suggests that melatonin levels are decreased in patients with Alzheimer's disease
In the United States, ramelteon is marketed for the treatment of insomnia characterized by difficulty with sleep onset and is under global development for the treatment of transient, chronic insomnia and circadian rhythm sleep disorders. It is believed that ramelteon works by binding melatonin to MT1/MT2 receptors in the suprachiasmatic nucleus which inhibits firing of specific neurons, which is thought to attenuate the alerting signal and allows the homeostatic mechanism to express itself and promote sleep.
Study participation is anticipated to be about 11 weeks (approximately 3 months).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||74 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects|
|Actual Study Start Date :||March 21, 2006|
|Actual Primary Completion Date :||August 1, 2007|
|Actual Study Completion Date :||August 20, 2007|
|Experimental: Ramelteon 8 mg QD||
Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
|Placebo Comparator: Placebo||
Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
- Mean Nighttime Total Sleep Time as determined by actigraphy. [ Time Frame: Week 1 ]
- Change from Baseline in Nighttime Total Sleep Time [ Time Frame: Weeks 2, 4, 6, and 8 or Final Visit ]
- Change from Baseline in Nighttime Wake After Sleep Onset per Actigraphy [ Time Frame: Weeks 2, 4, 6, and 8 or Final Visit ]
- Change from Baseline in Nighttime Number Of Awakenings per Actigraphy [ Time Frame: Weeks 2, 4, 6, and 8 or Final Visit ]
- Change from Baseline in Daytime Total Sleep Time [ Time Frame: Weeks 2, 4, 6, and 8 or Final Visit ]
- Change from Baseline in the ratio of Daytime Total Sleep Time to Nighttime Total Sleep Time. [ Time Frame: Weeks 2, 4, 6, and 8 or Final Visit ]
- Change from Baseline in Sleep Efficiency. [ Time Frame: Weeks 2, 4, 6, and 8 or Final Visit ]
- Percentage of subjects who experience Increase in Nighttime Total Sleep Time of 30 minutes. [ Time Frame: Weeks 2, 4, 6, and 8 or Final Visit ]
- Number of Daytime Naps. [ Time Frame: Weeks 2, 4, 6, and 8 or Final Visit ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00325728
|Study Director:||Medical Director Clinical Science||Takeda Global Research and Development|